{
    "clinical_study": {
        "@rank": "134557", 
        "arm_group": [
            {
                "arm_group_label": "oral placebo with nebulized intranasal levofloxacin", 
                "arm_group_type": "Active Comparator", 
                "description": "Placebo oral tablet by mouth daily for 14 consecutive days along with nebulized levofloxacin 125 mg twice daily for 14 consecutive days"
            }, 
            {
                "arm_group_label": "oral antibiotics with nebulized intranasal placebo", 
                "arm_group_type": "Active Comparator", 
                "description": "Levofloxacin 500 mg by mouth once daily for 14 consecutive days, along with intranasal placebo solution twice daily for 14 consecutive days."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to treat patients with a diagnosis of chronic rhinosinusitis\n      (CRS) and a history of bilateral endoscopic sinus surgery during times of worsening symptoms\n      and signs of acute infection on nasal endoscopy with one of two treatments: (1) oral\n      antibiotics and twice daily intranasal saline irrigations or (2) oral placebo and twice\n      daily intranasal antibiotic irrigations. The two treatments will be compared to see if there\n      is any difference in patient outcomes. This will help guide treatment strategies for\n      patients with CRS in the future."
        }, 
        "brief_title": "Oral Versus Topical Antibiotics for Chronic Rhinosinusitis Exacerbations", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Rhinosinusitis", 
        "condition_browse": {
            "mesh_term": "Sinusitis"
        }, 
        "detailed_description": {
            "textblock": "See brief summary."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Adults (age \u2265 18).\n\n          2. Diagnosis of CRS.\n\n          3. Worsening sinonasal symptoms.\n\n          4. Previous bilateral endoscopic sinus surgery (ESS) (including maxillary antrostomy and\n             anterior ethmoidectomy).\n\n          5. English speaking.\n\n          6. Open sinuses (open middle meatus bilaterally; determined on endoscopy).\n\n          7. Positive sinonasal culture (1+ or greater) with sensitivity to one of the pre-chosen\n             antibiotic regimens.\n\n        Exclusion Criteria:\n\n          1. Patients < 18 years of age.\n\n          2. Treatment with systemic or topical antibiotics within the last 1 month.\n\n          3. Pregnant women.\n\n          4. Non-English speaking persons.\n\n          5. Systemically ill at initial visit necessitating treatment prior to culture data.\n\n          6. Allergies to chosen susceptible antibiotics.\n\n          7. Sinonasal culture with less than 1+ growth.\n\n          8. Multiple organisms grown on culture that are not sensitive to a single antibiotic.\n\n          9. Patients with ciliary function disorders (cystic fibrosis, Kartagener's syndrome,\n             ciliary dyskinesia).\n\n         10. Patients with immunodeficiencies."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "70", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01988779", 
            "org_study_id": "45566"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "oral placebo with nebulized intranasal levofloxacin", 
                    "oral antibiotics with nebulized intranasal placebo"
                ], 
                "intervention_name": "oral levofloxacin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "oral placebo with nebulized intranasal levofloxacin", 
                    "oral antibiotics with nebulized intranasal placebo"
                ], 
                "intervention_name": "nebulized levofloxacin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Anti-Bacterial Agents", 
                "Ofloxacin", 
                "Antibiotics, Antitubercular"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "December 2, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Rochester", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "14642"
                }, 
                "name": "University of Rochester Department of Otolaryngology Head and Neck Surgery"
            }, 
            "investigator": [
                {
                    "last_name": "Alexis Strohl, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Li-Xing Man, MSc, MD, MPA", 
                    "role": "Principal Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Oral Versus Topical Antibiotic Therapy for Treatment of Chronic Rhinosinusitis Exacerbations", 
        "overall_contact": {
            "email": "Alexis_Strohl@urmc.rochester.edu", 
            "last_name": "Alexis Strohl, MD", 
            "phone": "585-758-5700"
        }, 
        "overall_official": {
            "affiliation": "University of Rochester", 
            "last_name": "Li-Xing Man, MD, MPA, Msc", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change in Rhinosinusitis Disability Index (RSDI) scores", 
            "safety_issue": "No", 
            "time_frame": "14 days after treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01988779"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Rochester", 
            "investigator_full_name": "Li-Xing Man", 
            "investigator_title": "M.D.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Endoscopy findings using POSE scores", 
                "safety_issue": "No", 
                "time_frame": "14 days after treatment"
            }, 
            {
                "measure": "Change in the total bacterial community following treatment as determined by RNA pyrosequencing.", 
                "safety_issue": "No", 
                "time_frame": "14 days after treatment"
            }, 
            {
                "measure": "Change in aerobic bacterial cultures performed via traditional microbiology plating techniques", 
                "safety_issue": "No", 
                "time_frame": "14 days after treatment"
            }
        ], 
        "source": "University of Rochester", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Rochester", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}